Nasopharyngeal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We previously reported that AQP-3 aquaglyceroporin and ClC-3 chloride channels could form complexes to regulate cell volume in nasopharyngeal carcinoma cells.
|
26794461 |
2016 |
Hypertrophic Cardiomyopathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
We also provide Clcn3 as a direct target of miR-1-3p which sheds light on the mechanism of HCM.
|
29885652 |
2018 |
Glioma
|
0.340 |
Biomarker
|
disease |
CTD_human |
Transcripts for ClC-2 thru ClC-7 were detected in a human glioma cell line by PCR, whereas only ClC-2, ClC-3, and ClC-5 protein could be identified by Western blot.
|
12843258 |
2003 |
Glioma
|
0.340 |
AlteredExpression
|
disease |
LHGDN |
Transcripts for ClC-2 thru ClC-7 were detected in a human glioma cell line by PCR, whereas only ClC-2, ClC-3, and ClC-5 protein could be identified by Western blot.
|
12843258 |
2003 |
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Together, our data suggest that upregulation of ClC-3 by IGF-1 contributes to cell proliferation and tumor growth in breast cancer, and ClC-3 deficiency suppresses cell proliferation and tumor growth via the IGF/IGF receptor/ERK pathway.
|
29963105 |
2018 |
Blindness
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Together with developmental retardation and higher mortality, the Clcn3-/- mice showed neurological manifestations such as blindness, motor coordination deficit, and spontaneous hyperlocomotion.
|
12059962 |
2002 |
Developmental delay (disorder)
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Together with developmental retardation and higher mortality, the Clcn3-/- mice showed neurological manifestations such as blindness, motor coordination deficit, and spontaneous hyperlocomotion.
|
12059962 |
2002 |
Global developmental delay
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together with developmental retardation and higher mortality, the Clcn3-/- mice showed neurological manifestations such as blindness, motor coordination deficit, and spontaneous hyperlocomotion.
|
12059962 |
2002 |
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
To assess the roles of CLCN3 in breast cancer, we next performed three-dimensional (3D) spheroid proliferation analyses using MCF10A-ErbB2 cells treated with MCF10A-neo-derived exosomes or CLCN3 shRNA stably expressing SKBR3 and MDA-MB-453 breast cancer cells.
|
31608175 |
2019 |
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
To assess the roles of CLCN3 in breast cancer, we next performed three-dimensional (3D) spheroid proliferation analyses using MCF10A-ErbB2 cells treated with MCF10A-neo-derived exosomes or CLCN3 shRNA stably expressing SKBR3 and MDA-MB-453 breast cancer cells.
|
31608175 |
2019 |
Heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
This review will highlight the major findings and recent advances in the study of ClC-3 Cl(-) channels in the cardiovascular system and discuss their important roles in cardiac and vascular remodeling during hypertension, myocardial hypertrophy, ischemia/reperfusion, and heart failure.
|
21602838 |
2011 |
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
This review will highlight the major findings and recent advances in the study of ClC-3 Cl(-) channels in the cardiovascular system and discuss their important roles in cardiac and vascular remodeling during hypertension, myocardial hypertrophy, ischemia/reperfusion, and heart failure.
|
21602838 |
2011 |
Hypertensive disease
|
0.010 |
Biomarker
|
group |
BEFREE |
This review will highlight the major findings and recent advances in the study of ClC-3 Cl(-) channels in the cardiovascular system and discuss their important roles in cardiac and vascular remodeling during hypertension, myocardial hypertrophy, ischemia/reperfusion, and heart failure.
|
21602838 |
2011 |
Neuronal Ceroid-Lipofuscinoses
|
0.210 |
Biomarker
|
disease |
MGD |
These results indicated that the neurodegeneration observed in the Clcn3-/- mice was caused by an abnormality in the machinery which degrades the cellular protein and was associated with the phenotype of neuronal ceroid lipofuscinosis (NCL).
|
12059962 |
2002 |
Neuronal Ceroid-Lipofuscinoses
|
0.210 |
Biomarker
|
disease |
BEFREE |
These results indicated that the neurodegeneration observed in the Clcn3-/- mice was caused by an abnormality in the machinery which degrades the cellular protein and was associated with the phenotype of neuronal ceroid lipofuscinosis (NCL).
|
12059962 |
2002 |
Malignant neoplasm of stomach
|
0.320 |
Biomarker
|
disease |
BEFREE |
These findings indicate the vital role of CLC-3 in gastric cancer progression and its potential role of a therapeutic target for treatment.
|
29795988 |
2018 |
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings indicate the vital role of CLC-3 in gastric cancer progression and its potential role of a therapeutic target for treatment.
|
29795988 |
2018 |
Endotoxemia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Therefore, the regulation of intestinal tissue integrity by ClC-3 is crucial for maintaining LPS-induced survival in mice with endotoxemia.
|
29972266 |
2018 |
Glioma
|
0.340 |
Biomarker
|
disease |
BEFREE |
Therefore, the present study explored the involvement of CLCN3 in cisplatin resistance in human glioma U251 cells.
|
29963152 |
2018 |
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Therefore, cytoplasmic ClC-3 plays an active and key role in tumor metastasis and may be a valuable prognostic biomarker and a therapeutic target to prevent tumor spread.
|
25537517 |
2015 |
Secondary Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Therefore, cytoplasmic ClC-3 plays an active and key role in tumor metastasis and may be a valuable prognostic biomarker and a therapeutic target to prevent tumor spread.
|
25537517 |
2015 |
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
The purpose of this study was to evaluate whether ClC-3 influences the migration and invasion of cervical squamous cell carcinoma cells and its possible mechanisms.
|
30905432 |
2019 |
Malignant neoplasm of stomach
|
0.320 |
Biomarker
|
disease |
BEFREE |
The molecular mechanisms by which CLC-3 is regulated in GC are unclear.
|
30217218 |
2018 |
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The molecular mechanisms by which CLC-3 is regulated in GC are unclear.
|
30217218 |
2018 |
Pneumonitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The liver and lung inflammations in mice with ClC-3 deletion were significantly less than those in wild-type mice, and the levels of TNF-α and MIP-2 in serum were lower than those of wild-type mice.
|
29972266 |
2018 |